Celltrion Expands Market Presence in Spain and Portugal Through Tender Wins
Celltrion is rapidly strengthening its presence in Spain and Portugal, securing a series of government and regional tenders while expanding sales and marketing activities to drive prescriptions and product supply across the two European markets.In Spain, one of the EU’s five largest pharmaceutical m
Celltrion is expanding its market presence in Spain and Portugal by winning government and regional tenders, boosting sales and marketing efforts to increase prescriptions and product supply. In Spain, the country's fifth-largest pharmaceutical market, Celltrion's omalizumab biosimilar Omlyclo has gained significant traction in treating chronic spontaneous urticaria and allergic asthma.
Celltrion Spain secured contracts in four major regions - Catalonia, the Basque Country, Asturias, and Valencia - during the first half of the year, with Omlyclo's market share in Spain surpassing 90% as of June. The rapid uptake can be attributed to Omlyclo's unique 150mg autoinjector formulation, longer shelf life, and stability data supporting room temperature storage.
Celltrion Spain is actively promoting these product advantages through targeted sales and marketing efforts aimed at healthcare professionals and pharmacy stakeholders, emphasizing potential healthcare cost savings associated with biosimilar adoption. Celltrion's Actemra biosimilar Aptozma, which contains tocilizumab, has also expanded its presence in Spain, securing over half of the market by the second quarter.
Similarly, in neighboring Portugal, Celltrion won tenders for its autoimmune disease treatments, including infliximab biosimilar Remsima, adalimumab biosimilar Yuflyma, and ustekinumab biosimilar Steqeyma, demonstrating the company's growing competitiveness beyond the autoimmune disease segment.
Written by urgent.news from Korea IT Times's reporting — not their text. Machine-written — it may contain errors, so check the original before relying on it.
